Combination Therapy Improves Crohn's Treatment Durability
Adults with Crohn's disease may sustain the effects of anti-TNF treatment longer by continuing immunomodulators.
Updated on Oct. 21, 2026 in Nutrition
Live Poll
Is it worth continuing long-term combination medication if it improves the durability of your primary treatment?
Data from the PROFILE trial analysis presented in October 2026 suggests that continuing immunomodulator therapy alongside anti-TNF drugs significantly improves treatment durability for Crohn's disease. Patients managing their condition may see this as a factor in long-term treatment planning.
Why it matters
For adults with newly diagnosed Crohn's disease, maintaining combination therapy may prevent the loss of response to anti-TNF medications. This analysis helps clarify how different treatment strategies affect the sustained success of therapies over several years.
This analysis of 358 participants in the PROFILE trial compared sustained combination therapy to monotherapy over a median follow-up of 5 years. Results showed a 75% persistence rate for those on combination therapy versus 40%-45% for those on monotherapy, though optimal withdrawal timing is unknown.
The details
The study compared immediate top-down combination therapy—often using thiopurines—against an accelerated step-up strategy. By combining these agents, clinicians were able to reduce both immunogenic treatment failure, where the body develops antibodies against the drug, and nonimmunogenic failure. These factors appear to contribute to the median anti-TNF persistence of 73 months observed in the trial cohort.
Timeline
October 2026: Findings presented at United European Gastroenterology Week.
5 years: Median follow-up duration for study participants.
73 months: Median persistence of anti-TNF treatment for patients.
Health Landscape
This analysis builds upon findings from the PROFILE trial to refine how clinicians approach long-term maintenance in Crohn's disease management. It highlights a shift in understanding how sustained immunomodulator use influences the longevity of anti-TNF therapy compared to standard step-up approaches.
If you are currently managing Crohn's disease with anti-TNF medication, this data highlights the importance of discussing treatment durability with your gastroenterologist. Be sure to ask about the specific benefits and risks of maintaining an immunomodulator over a multi-year period.
The takeaway
Maintaining combination therapy appears to be a critical factor in the long-term effectiveness of anti-TNF drugs for Crohn's disease. If you are starting or currently using these treatments, keep a record of your therapy timeline to facilitate informed conversations with your care team.
Further reading
For more on managing long-term treatment strategies, visit Nutrition.
Source note: This article includes information reported by Medscape.
Live Poll
Is it worth continuing long-term combination medication if it improves the durability of your primary treatment?
